Search

Asabys launches a fund of up to €120M to transform scientific discoveries into innovative healthcare companies, reinforcing its commitment to technology transfer and the creation of deep tech

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off.

Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector.

Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector quality, and low batch variability.

We welcome the Biotech Act I, but believe its ambition and level of specificity must be strengthened to ensure a real impact on funding, industrial scale-up, and biotechnology innovation in Europe; a

Rubén Pérez-Mañanes is an orthopaedic oncology surgeon at the HGUGM (Gregorio Marañón University General Hospital), deputy director of the Gregorio Marañón Health Research Institute and an ANECA

Meet StablePharma, our new member. We spoke with Lorena Carmona Rodríguez, Lab Manager/Senior Scientist.

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12

These results come from a preclinical study conducted by the Cell Engineering team at Integra Therapeutics using the FiCAT gene-writing platform.

Meet AllBiotech, our new member. We spoke with Pablo Goñi, CEO.

The company presented its new Branded Ingredient at Vitafoods Europe, the nutraceutical industry trade show, which took place this week in Barcelona

The Dutch company is bolstering Málaga’s advanced technology ecosystem with a total investment of €32 million.

Innovation in healthcare does not arise solely from good ideas, but from an institutional architecture capable of attracting talent, coordinating capabilities and accelerating translation.

The agreement combines the preclinical models developed by the Institute of Biomedical Research of Barcelona (IIBB-CSIC) with the computational design platform of the company Chemotargets, based at

Meet PLOID AI, our new member. We spoke with Adolfo Gastalver Rubio and Federico Jurado Ruiz, CO-Founders.

Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June.

MedTech Barcelona took part in the Spain–United States Business Meeting in Boston, held on April 13 and 14.

The Bilbao Exhibition Centre will host the next edition of BIOSPAIN from September 29 to October 1.

At AseBio, we reaffirm our commitment to continuing to work with European and national institutions to ensure that the implementation of the Regulation fully harnesses the potential of NGTs in support

The strategic framework agreement deepens the long-standing partnership, leveraging Artificial Intelligence and High-Performance Computing to identify new opportunities of collaboration in the